<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3145">
  <stage>Registered</stage>
  <submitdate>14/04/2011</submitdate>
  <approvaldate>14/04/2011</approvaldate>
  <nctid>NCT01339884</nctid>
  <trial_identification>
    <studytitle>A Study of Resveratrol as Treatment for Friedreich Ataxia</studytitle>
    <scientifictitle>An Open Label Clinical Pilot Study of Resveratrol as Treatment for Friedreich Ataxia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>10358B</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Friedreich Ataxia</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Neurodegenerative diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Resveratrol

Active Comparator: Resveratrol, 1g daily - 15 participants will receive resveratrol 1g daily

Active Comparator: Resveratrol, 5g daily - 15 participants will receive resveratrol, 5g daily


Treatment: drugs: Resveratrol
Resveratrol 1g daily (500mg twice daily) for 12 weeks Resveratrol 5 daily (2.5g twice daily) for 12 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Lymphocyte frataxin level - Change in lymphocyte frataxin levels at 12 weeks compared to baseline</outcome>
      <timepoint>12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Oxidative stress markers - Oxidative stress, as measured by a) plasma F2-isoprostanes and b) urinary 8-hydroxyl-2-deoxyguanosine levels at 12 weeks compared to baseline</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical rating scales of ataxia - Clinical rating scales of ataxia at 12 weeks will be compared to baseline. This will include: a) Friedreich Ataxia Rating Scale (FARS) b) International Cooperative Ataxia Rating Scale (ICARS) c) Scale for the Assessment and Rating of Ataxia (SARA) d) Friedreich Ataxia Functional Composite</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Echocardiogram measures - Changes in structural and functional 3D echocardiogram measures from baseline to 12 weeks will be reported</outcome>
      <timepoint>12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic studies of resveratrol - Pharmacokinetic data will be collected 45, 90 and 120 minutes after the first dose of resveratrol. Plasma concentration of resveratrol and its sulfate and glucuronide metabolites will be measured in ng/mL.</outcome>
      <timepoint>First 2 hours post dose</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Adults with Friedreich ataxia due to homozygosity for the GAA repeat expansion in
             intron 1 of the FXN gene

          -  Functional stage on the Ataxia subscale of the FARS of 1 or higher</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Women who are pregnant or lactating

          -  Active arrythmias or significant cardiac insufficiency

          -  Use of idebenone, Coenzyme Q or vitamin E within 30 days prior to enrolment

          -  Use of amiodarone or other medications which may have clinically significant drug
             interactions that cannot be safely monitored</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>27</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Monash Medical Centre, Southern Health - Clayton, Melbourne</hospital>
    <postcode>3168 - Clayton, Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Murdoch Childrens Research Institute</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Friedreich's Ataxia Research Alliance</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the effect of two doses of resveratrol taken for a
      12 week period, on frataxin levels in individuals with Friedreich ataxia. This study will
      also measure the effect of resveratrol on markers of oxidative stress, clinical measures of
      ataxia, and cardiac parameters.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01339884</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Martin Delatycki, MBBS PhD</name>
      <address>Murdoch Childrens Research Institute</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>